| Document |
Document Title |
|
WO/2023/202583A1 |
Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...
|
|
WO/2023/205226A1 |
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting mutant KIT prote...
|
|
WO/2023/202664A1 |
Disclosed herein are fused bi-cyclic compounds used as Small Molecule IL-17A Modulators. Disclosed herein is the use of these Small Molecule IL-17A Modulators for the use of decreasing IL-17 activity by inhibition, and the use of such co...
|
|
WO/2023/197987A1 |
Disclosed are a novel compound as represented by formula (I-b) having an ENPP1 inhibitory activity, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating cell p...
|
|
WO/2023/200196A1 |
The present invention relates to an organic compound employed in an organic layer in an organic light-emitting device, such as a hole transport layer and an electron blocking layer. The organic compound according to the present invention...
|
|
WO/2023/200195A1 |
The present invention relates to an organic compound, which is employed for an organic layer, such as a hole transport layer or an electron block layer, of an organic light emitting diode. The organic compound according to the present in...
|
|
WO/2023/196512A1 |
Disclosed are compounds of formula I, formula I-1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof that are useful for modulating or degrading bromodomain (e.g., BRD4).
|
|
WO/2023/195787A1 |
An organic compound represented by chemical formula 1 of the present invention can implement excellent hole transfer characteristics. In addition, at least one of a hole transport layer and a hole transport aid layer of an organic light ...
|
|
WO/2023/194458A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a meth...
|
|
WO/2023/195791A1 |
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...
|
|
WO/2023/191353A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, an organic light-emitting device comprising same, and a composition comprising same for forming an organic layer.
|
|
WO/2023/180964A1 |
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...
|
|
WO/2023/180189A1 |
Disclosed are novel viral Mpro inhibitors according to Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to inhibit Mpro and...
|
|
WO/2023/182519A1 |
An ascorbic acid derivative or a salt thereof that contains a structure in which at least one of hydroxyl groups contained in ascorbic acid has been substituted with an ether bond attached to a carbon atom.
|
|
WO/2023/178302A1 |
Natural product-like compounds are derived from the sesquiterpene lactone parthenolide. Methods are provided for the generation of novel natural product-like molecules obtained through the chemoenzymatic reelaboration and modification of...
|
|
WO/2023/171920A1 |
Provided is a high-refractive-index carbazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...
|
|
WO/2023/171781A1 |
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treat...
|
|
WO/2023/169436A1 |
Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/160614A1 |
Disclosed in the present invention are a compound as an FAK inhibitor and a use thereof. Specifically, involved are a compound represented by general formula (1) and a preparation method therefor, and a use of the compound represented by...
|
|
WO/2023/155710A1 |
The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
|
|
WO/2023/155927A1 |
The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...
|
|
WO/2023/153169A1 |
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...
|
|
WO/2023/150776A1 |
The present disclosure provides water-soluble and low-aggregation NIR- and SWIR- active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.
|
|
WO/2023/146244A1 |
The present disclosure provides a benzodioxane scaffold compound having AIMP2-DX2 inhibitory activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising such a compound or a pharm...
|
|
WO/2023/145758A1 |
Provided is a method for producing a fluorine-containing phthalic acid derivative, whereby a fluorine-containing phthalic acid derivative can be obtained using a simple process. This method for producing a fluorine-containing phthalic ac...
|
|
WO/2023/139091A1 |
Identification of small organic molecules capable of stimulating aerobic glycolysis and cone survival would lead to the conception of new therapies of the retinal degenerative diseases.Now the inventors identified Geralexin, an acetogeni...
|
|
WO/2023/137453A1 |
The present disclosure relates to compounds Formula (I): methods for making the compounds and methods for their use.
|
|
WO/2023/135107A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2023/137446A1 |
The present disclosure relates to prodrugs of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), methods for making the prodrugs and the methods for their use in treating brain and neurological disorders.
|
|
WO/2023/131868A1 |
The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.
|
|
WO/2023/132490A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/132489A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/125716A1 |
Provided in the present invention are a class of quinoline compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided in the present invention are a compound as shown in formula ...
|
|
WO/2023/127809A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/127805A1 |
In the production of crops in agriculture, horticulture, and the like, the occurrence of damage by pests and the like has been still a major issue, and therefore the development of new agricultural/horticultural pesticides has been deman...
|
|
WO/2023/121992A1 |
The invention provides new heterocyclic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, compositions including the co...
|
|
WO/2023/118715A1 |
The present invention relates to a process for synthesising 5-((2-methyl-1H-imidazol-1-yl)methyl)furan-2-carbaldehyde from a mixture comprising a carbohydrate, an alkali metal chloride or alkaline earth metal chloride, hydrochloric acid,...
|
|
WO/2023/108363A1 |
Provided are compounds of Formula (I) and the preparation methods of these compounds, and their use as P2Y12 receptor antagonists in the treatment and/or prevention of thrombosis or related disorders.
|
|
WO/2023/108036A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and/or antagonists of cannabi...
|
|
WO/2023/104201A1 |
An aryl C-glucoside derivative, a preparation method therefor and the use thereof. Specifically provided are an aryl C-glucoside derivative as shown in formula I, a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharma...
|
|
WO/2023/103850A1 |
Provided are a small molecule STING agonist, a preparation method therefor, and an application. Specifically, the present invention provides the compound represented by structural formula I, the compound having STING agonist activity. Th...
|
|
WO/2023/097697A1 |
Provided is a method for synthesizing (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)oxazolidin-2-on
e, the route of the method being as follows: [Route 1], wherein X is Br, Cl or I, and R1 and R2 are protective groups that can be removed....
|
|
WO/2023/096209A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an...
|
|
WO/2023/092195A1 |
Analogues of 3,4-methylenedioxymethamphetamine (MDMA), processes for their preparation, medicaments and medical methods of treatment comprising said MDMA analogues, and medical uses of said MDMA analogues. The MDMA analogues are capable ...
|
|
WO/2023/094734A1 |
The present invention relates to novel ligands for vesicular glutamate transporters, VGLUTs, and the use thereof in diagnostic methods and therapeutic applications. The invention also relates to the use of fluorescent properties of novel...
|
|
WO/2023/090822A1 |
The present invention provides a cannabichromenic acid derivative, a preparation method therefor, and a composition comprising same for improving cognitive function. A novel cannabichromenic acid derivative of the present invention has b...
|
|
WO/2023/092107A1 |
The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/091674A1 |
Described herein are compounds which are inhibitors of oncogenic and wild-type SHP2 and methods of treatment using SHP2 inhibitors.
|
